Cynata Therapeutics Limited (AU:CYP)
ASX:CYP
Want to see AU:CYP full AI Analyst Report?
Top Page
Cynata Therapeutics Limited
(Sydney:CYP)
Select Model
Select Model
Rating:41Neutral
Price Target:
AU$0.01
▼(-95.52% Downside)
Action:Reiterated
Date:06/25/26
The score is driven primarily by weak financial performance (large ongoing losses and negative cash flow, despite some recent stabilization) and very bearish technical momentum (price below all major moving averages with negative MACD and extremely low RSI). Valuation provides limited support because the company is loss-making (negative P/E) and no dividend yield is available.
Positive Factors
Scalable iPSC-derived MSC platform
Cynata's iPSC-derived, allogeneic MSC platform is a structural advantage: off-the-shelf manufacturing targets consistency and scalability versus donor-dependent approaches. That durable manufacturing edge can lower batch variability and support commercial supply if clinical programs succeed.
Negative Factors
Persistent negative cash flow
Sustained negative operating and free cash flows mean the company relies on external financing to fund operations and trials. Over months this increases dilution or forces costly financing, constrains investment pacing, and elevates execution risk for late-stage programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Scalable iPSC-derived MSC platform
Cynata's iPSC-derived, allogeneic MSC platform is a structural advantage: off-the-shelf manufacturing targets consistency and scalability versus donor-dependent approaches. That durable manufacturing edge can lower batch variability and support commercial supply if clinical programs succeed.
Read all positive factors
Cynata Therapeutics Limited (CYP) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$3.90M
Dividend YieldN/A
Average Volume (3M)233.82K
Price to Earnings (P/E)―
Beta (1Y)0.72
Revenue GrowthN/A
EPS Growth24.59%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.05
Shares Outstanding243,454,380
10 Day Avg. Volume170,513
30 Day Avg. Volume233,823
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)5.14
Price to Sales (P/S)16.31
P/FCF Ratio-3.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.08
Revenue Forecast (FY)AU$17.10M
Cynata Therapeutics Limited Business Overview & Revenue Model
Company Description
Headquartered in Cremorne, Australia, Cynata Therapeutics Limited, established in 2003 and formerly known as Eco Quest Limited until its 2013 rebranding, specializes in the development and commercialization of its proprietary Cymerus mesenchymal s...
How the Company Makes Money
Cynata Therapeutics is a clinical-stage biotechnology company and, based on publicly available high-level information, it does not appear to have an established, recurring product-revenue base from commercialized therapeutics; therefore, detailed,...
Cynata Therapeutics Limited Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
58
Neutral
Cash Flow
24
Negative
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.89M | 2.32M | 1.65M | 7.77M | 1.55M |
| Gross Profit | 1.89M | 2.32M | 1.37M | 7.49M | 1.27M |
| EBITDA | -9.33M | -9.95M | -15.65M | -6.00M | -8.80M |
| Net Income | -9.39M | -9.74M | -14.28M | -5.45M | -7.69M |
Balance Sheet | |||||
| Total Assets | 7.20M | 8.39M | 18.99M | 26.55M | 29.97M |
| Cash, Cash Equivalents and Short-Term Investments | 5.05M | 6.21M | 16.17M | 23.80M | 26.72M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.22M | 1.17M | 2.26M | 2.59M | 1.60M |
| Stockholders Equity | 5.98M | 7.22M | 16.73M | 23.96M | 28.37M |
Cash Flow | |||||
| Free Cash Flow | -8.77M | -9.96M | -14.28M | -3.30M | -5.16M |
| Operating Cash Flow | -8.72M | -9.96M | -14.28M | -3.30M | -5.16M |
| Investing Cash Flow | -50.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 7.61M | 0.00 | 6.72M | 210.12K | 18.20M |
Cynata Therapeutics Limited Technical Analysis
Negative
0.29
Price Trends
0.28
Negative
0.31
Negative
0.29
Negative
Market Momentum
-0.07
Positive
10.43
Positive
0.38
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CYP, the sentiment is Negative. The current price of 0.29 is above the 20-day moving average (MA) of 0.22, above the 50-day MA of 0.28, and above the 200-day MA of 0.29, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 10.43 is Positive, neither overbought nor oversold. The STOCH value of 0.38 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:CYP.
Cynata Therapeutics Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | AU$2.81B | -23.95 | -14.02% | ― | 1069.25% | 18.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$12.57M | -1.84 | -218.76% | ― | 76.94% | 42.95% | |
44 Neutral | AU$5.93M | -1.57 | -29.91% | ― | 82.28% | 13.33% | |
42 Neutral | AU$22.28M | 20.00 | -49.25% | ― | ― | 25.00% | |
41 Neutral | AU$3.90M | -0.33 | -179.37% | ― | ― | 24.59% | |
41 Neutral | AU$202.83M | -14.24 | -44.80% | ― | 49.03% | -232.68% |
* Healthcare Sector Average
AU:CYP
Cynata Therapeutics Limited
0.01
-0.14
-90.97%
AU:1AI
Living Cell Technologies
0.01
0.00
0.00%
AU:MSB
Mesoblast Limited
2.23
0.61
37.65%
AU:OCC
Orthocell Ltd
0.74
-0.48
-39.26%
AU:TRP
Tissue Repair Ltd
0.10
-0.08
-44.44%
AU:CMB
Regeneus Ltd.
0.46
0.25
119.05%
Cynata Therapeutics Limited Corporate Events
Bioscience Fund Exits Substantial Holding in Cynata Therapeutics
Jun 23, 2026
Phillip Asset Management, acting for Bioscience Managers Translation Fund I, has ceased to be a substantial shareholder in Cynata Therapeutics after disposing of its remaining voting securities. The fund sold tranches of Cynata shares on 19 June a...
Cynata to Host Investor Webinar on Results Update
Jun 21, 2026
Cynata Therapeutics has scheduled an investor webinar for 22 June 2026, hosted by CEO and Managing Director Dr. Kilian Kelly and Chair Dr. Geoff Brooke, to provide a results update to shareholders. The company will make the webinar presentation ma...
Cynata’s CYP-004 Fails to Outperform Placebo in Phase 3 Knee Osteoarthritis Trial
Jun 19, 2026
Cynata Therapeutics reported top-line results from the University of Sydney’s Phase 3 SCUlpTOR trial of its Cymerus-derived CYP-004 cell therapy in knee osteoarthritis. The study found no safety concerns and showed substantial pain reduction...
Cynata Halts CYP-001 GvHD Trial After Phase 2 Misses Efficacy Goals
Jun 17, 2026
Cynata Therapeutics reported primary evaluation results from its Phase 2 trial of CYP-001 in high-risk acute graft versus host disease, showing no safety concerns but no significant efficacy differences versus steroid plus placebo treatment. The t...
Cynata Seeks ASX Trading Suspension Ahead of Key Clinical Trial Results
Jun 16, 2026
Cynata Therapeutics has requested a voluntary suspension of trading in its shares on the ASX, with the exchange implementing the halt under Listing Rule 17.2 pending a material announcement. The suspension is expected to remain in place until eith...
Cynata Sets June–July Timeline for Pivotal Stem Cell Trial Readouts
May 26, 2026
Cynata Therapeutics has provided an update on the timelines for two key clinical readouts from its Cymerus iPSC-derived mesenchymal stem cell pipeline, underscoring a pivotal period for the company’s late-stage programs. The University of Sy...
Cynata completes $1.5m share placement to fund Cymerus cell therapy pipeline
May 8, 2026
Cynata Therapeutics has completed a share placement, issuing 6,000,000 fully paid ordinary shares at $0.25 each, raising additional equity capital without the need for a prospectus under Australian corporations law. The company confirmed it is com...
Cynata Seeks ASX Quotation for 6 Million New Shares
May 8, 2026
Cynata Therapeutics Limited, an ASX-listed biotechnology company trading under the ticker CYP, develops therapeutic products in the life sciences sector and funds its operations through equity capital raisings. The company focuses on advancing its...
Cynata Plans Placement of Up to 6 Million New Shares
May 3, 2026
Cynata Therapeutics Limited has announced a proposed issue of up to 6,000,000 ordinary fully paid shares on the ASX under a placement or similar capital-raising structure. The new securities, expected to be issued on 8 May 2026, indicate a move to...
Cynata Nears Key Trial Readouts as Cell Therapy Sector Gains Traction
Apr 30, 2026
Cynata Therapeutics is advancing a pipeline of iPSC-derived mesenchymal stem cell therapies built on its Cymerus platform, aiming to deliver scalable, consistent cell products for immune and inflammatory diseases. The company is positioned within ...
Cynata Seeks Trading Halt Ahead of Share Placement Capital Raising
Apr 30, 2026
Cynata Therapeutics has requested an immediate trading halt on its ASX‑listed securities as it prepares to announce a proposed capital raising via a share placement. The halt will remain in place until either the company releases details of ...
Cynata Options Expire Unexercised, Streamlining Capital Structure
Apr 6, 2026
Cynata Therapeutics Limited has announced the cessation of three tranches of listed options on the ASX, each with different exercise prices of $0.30, $0.40 and $0.50, after a total of 3,000,000 options expired unexercised on 2 April 2026. The expi...
Cynata Reaches Key Phase 2 Milestone in aGvHD as Late-Stage Cell Therapy Pipeline Advances
Mar 29, 2026
Cynata Therapeutics has completed the 100-day primary evaluation period for all 65 participants in its Phase 2 trial of CYP-001 in adults with acute graft versus host disease, marking the last-patient, last-visit milestone in this randomized, doub...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.